Merck advanced a vaccine trial evaluating safety and tolerability, presented at American Diabetes Association sessions.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck advanced a vaccine trial evaluating safety and tolerability, presented at American Diabetes Association sessions.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
mash
fast genome and metagenome distance estimation using MinHash
Nothing else this week.
-
Merck
public company in Indonesia
Related events
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Moderna and Merck are developing cancer vaccines in partnership, while Moderna is also seeking approval for its seasonal influenza vaccine.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.
- Moderna, Merck, and Georgetown Lombardi Comprehensive Cancer Center are collaborating on developing a personalized cancer vaccine combination.
Coverage
Newest first; wire copies grouped- GlobeNewswireOPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NA